There are currently 683 clinical trials in Milwaukee, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical College of Wisconsin, Children's Hospital of Wisconsin, Aurora Saint Luke's Medical Center and Aurora Sinai Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Recruiting
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab bi... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
03/11/2025
Locations: Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Neuroblastoma, Ganglioneuroblastoma, Nodular
Evaluation of a Simple-Prep Controlled Embolic
Recruiting
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Embolism, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Portal Vein Embolism
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840723, Milwaukee, Wisconsin
Conditions: Chronic Obstructive Pulmonary Disease
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Metastatic Non Small Cell Lung Cancer
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Recruiting
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin +3 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Recruiting
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin +2 locations
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Localized Breast Carcinoma
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2025
Locations: Comprehensive Center for Bleeding Disorders, Milwaukee, Wisconsin
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/11/2025
Locations: Research Site, Milwaukee, Wisconsin
Conditions: Asthma
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Recruiting
This is a study evaluating the safety, pharmacokinetics, and efficacy of MK-1084 alone, and MK-1084 plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0262), Milwaukee, Wisconsin
Conditions: Advanced Solid Tumors
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Recruiting
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Endometrial Cancer
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Recruiting
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Brain Metastases